Immunotherapy and targeted therapy for her2-positive digestive cancers
Treatments studied
Part of Digestive system clinical trials.
This study tests a combination of two medicines (sintilimab, an immunotherapy that boosts your immune system, and pyrotinib, a targeted pill that attacks HER2-positive cancer) sometimes plus chemotherapy, for people with advanced digestive system cancers that are HER2-positive.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have one of these cancers: stomach, colorectal, liver (hepatocellular), bile duct, or pancreatic cancer that cannot be removed with surgery or has spread to other parts of the body.
- Your cancer must be HER2-positive (a specific protein marker found in a lab test).
- You can be new to treatment, or you may have had one prior line of treatment that stopped working or caused side effects.
- You must be in reasonably good health, with adequate liver, kidney, and blood function.
- You must not have been treated before with a HER2-targeted therapy like Herceptin (trastuzumab).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new approach for stomach cancer that has spread to nearby tissues but not to other organs. You would get a short course of radiation, followed by a combination of targeted therapy (Disitamab Vedotin), chemotherapy (S-1), and immunotherapy (Sintilimab) before surgery to shrink the tumor and improve outcomes.
This trial tests a new combination of drugs (RC48, sintilimab, and SOX chemotherapy) for people with stomach or gastroesophageal junction cancer that cannot be removed by surgery, has not been treated before, and has a specific HER2 score (1+ or 2+). The goal is to shrink the tumor enough to possibly allow surgical removal.
This trial tests a combination of an immunotherapy drug (sintilimab) and chemotherapy (FOLFIRI) for people with advanced stomach cancer that has not responded to first treatment. It aims to see if this combination can help control the cancer.
This trial tests a combination of an immunotherapy drug (sintilimab) and two chemotherapy drugs (nab-paclitaxel and tegafur) as a first treatment for stomach or gastroesophageal junction cancer that cannot be removed by surgery or has spread. The goal is to see if this combination helps people live longer and controls the cancer better.
This study tests a combination of three treatments for advanced stomach cancer that is HER2-positive. The treatments are RC48, an antibody-drug conjugate that targets HER2 on cancer cells, sintilimab, which helps the immune system fight cancer, and S-1, a chemotherapy drug. The goal is to see if the combination is safe and effective as a first-line treatment.
This trial tests a combination of two targeted drugs (disitamab vedotin and sintilimab) along with radiation for HER2-positive stomach cancer that has stopped responding to standard treatments. The goal is to see if this combo can shrink tumors and help you live longer.
Hear when a new Advanced Digestive System Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.